Trending: Roche to Buy Telavant From Roivant and Pfizer
1504 ET -- Roche Holding and Pfizer are among the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Roche agreed to buy Telavant Holdings from Roivant Sciences and Pfizer, a deal that includes $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is developing a bowel-disease treatment. On Friday, Pfizer said the Food and Drug Administration approved Penbraya, a vaccine for meningococcal disease. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
October 23, 2023 15:26 ET (19:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors